{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:27:32Z","timestamp":1787761652811,"version":"build-2784847793"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      (TB) practically affects any part of the body, but when the brain is involved, the consequences are devastating. Tuberculous meningitis (TBM) is the most severe form of drug-susceptible TB, with an estimation of more than 100,000 new cases occurring every year and a high mortality rate globally. The treatment strategy is based on pulmonary TB (PTB) management regimens which consider rifampicin as the backbone. Optimal treatment regimens for PTB may not be the most effective option for TBM due to difference in TB drug penetration across the blood\u2013cerebrospinal fluid barrier, hence the need for other treatment options. This study aims to review the efficacy and safety of higher doses of rifampicin (&gt;10 mg\/kg) compared to 10 mg\/kg rifampicin as part of standard therapy for the treatment of TBM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis was conducted to assess the efficacy and safety of high-dose rifampicin for TBM. A search was done on PubMed, Google Scholar, and Cochrane library databases without publication date limit to identify studies providing data on the use of high-dose rifampicin for the treatment of TBM. Titles and abstracts were screened for relevance by three reviewers. Two reviewers used a predefined checklist on the inclusion criteria to assess full text for their eligibility in the review. A heterogeneity test was conducted to assess the variations among study outcomes. The risk ratio (RR) with a 95% confidence interval (CI) was calculated as a measure of intervention effect. The study is registered on PROSPERO and the registration number is CRD42020212737.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Five Phase 2 trials with a total of 1028 participants were included in this meta-analysis. All the five trials were used to analyze safety data, which found that there was no significant increase in the risk of Grade 3\u20135 adverse events in high-dose rifampicin (RR = 1.05; 95% CI = 0.95\u20131.18). Only four of them were included for the analysis of efficacy. The findings indicated that exposure to high-dose rifampicin is not associated with a reduced risk of mortality (RR = 0.95; 95% CI = 0.78\u20131.16).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>It can be concluded from this meta-analysis that there is no significant relation of high-dose rifampicin with adverse events and the reduction of mortality in TBM patients. Whether in future optimized TBM treatment regimen will include high-dose rifampicin or not should be determined by a large-scale clinical trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_135_21","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T08:57:49Z","timestamp":1682067469000},"page":"312-319","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Safety and Efficacy of High-Dose Rifampicin in the Management of Tuberculosis Meningitis"],"prefix":"10.4103","volume":"10","author":[{"given":"Loveness","family":"Charlie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon Mequante","family":"Abay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Tesfaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald Nachipo","family":"Mlera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Mwango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Goretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-14-20240902","doi-asserted-by":"crossref","first-page":"e01014","DOI":"10.1128\/AAC.01014-18","article-title":"Double-blind, randomized, placebo-controlled phase ii dose-finding study to evaluate high-dose rifampin for tuberculous meningitis","volume":"62","author":"Dian","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-14-20240902","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/jcrsm.jcrsm_17_19","article-title":"Tuberculous meningitis: A narrative review","volume":"5","author":"Vinny","year":"2019","journal-title":"J Curr Res Sci Med"},{"key":"R4-14-20240902","first-page":"CD002244","article-title":"Corticosteroids for managing tuberculous meningitis","volume":"4","author":"Prasad","year":"2016","journal-title":"Cochrane Database of Syst Rev"},{"key":"R5-14-20240902","doi-asserted-by":"crossref","first-page":"83","DOI":"10.12688\/wellcomeopenres.14691.1","article-title":"High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: A phase II open-label randomised controlled trial (the RifT study)","volume":"3","author":"Cresswell","year":"2018","journal-title":"Wellcome Open Res"},{"key":"R6-14-20240902","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"N Engl J Med"},{"key":"R7-14-20240902","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis","volume":"13","author":"Wilkinson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"R8-14-20240902","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2019.04.026","article-title":"Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis","volume":"84","author":"Mezochow","year":"2019","journal-title":"Int J Infect Dis"},{"key":"R9-14-20240902","doi-asserted-by":"crossref","first-page":"190","DOI":"10.12688\/wellcomeopenres.15565.1","article-title":"High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study)","volume":"4","author":"Marais","year":"2019","journal-title":"Wellcome Open Res"},{"key":"R10-14-20240902","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","author":"Heemskerk","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-14-20240902","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/cid\/ciy026","article-title":"The potential for treatment shortening with higher rifampicin doses: Relating drug exposure to treatment response in patients with pulmonary tuberculosis","volume":"67","author":"Svensson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R12-14-20240902","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1093\/cid\/ciz1202","article-title":"Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing","volume":"71","author":"Susanto","year":"2019","journal-title":"Clinical Infectious Diseases"},{"key":"R13-14-20240902","first-page":"305","article-title":"Higher-dose rifampin for the treatment of pulmonary tuberculosis: A systematic review","volume":"15","author":"Steingart","year":"2011","journal-title":"Int Union Against Tuberc Lung Dis"},{"key":"R14-14-20240902","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/AAC.01474-06","article-title":"Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears","volume":"51","author":"Diacon","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-14-20240902","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1164\/rccm.201207-1210OC","article-title":"Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model","volume":"187","author":"De Steenwinkel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R16-14-20240902","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/infdis\/jiy242","article-title":"Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations","volume":"218","author":"Svensson","year":"2018","journal-title":"J Infect Dis"},{"key":"R18-14-20240902","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"For the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R19-14-20240902","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0304-3959(99)00302-4","article-title":"An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data","volume":"85","author":"Gavaghan","year":"2000","journal-title":"Pain"},{"key":"R21-14-20240902","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jrsm.1259","article-title":"Methods for including information from multi-arm trials in pairwise meta-analysis","volume":"8","author":"R\u00fccker","year":"2017","journal-title":"Res Synth Methods"},{"key":"R22-14-20240902","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: An open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"R23-14-20240902","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2016.06.016","article-title":"Pharmacokinetics and safety\/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients","volume":"48","author":"Yunivita","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R24-14-20240902","first-page":"1","article-title":"High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly HIV-positive Ugandan adults: A phase II open-label randomised controlled trial","volume":"1","author":"Cresswell","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R25-14-20240902","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/00002030-200007070-00013","article-title":"Impact of HIV infection on meningitis in Harare, Zimbabwe: A prospective study of 406 predominantly adult patients","volume":"14","author":"Hakim","year":"2000","journal-title":"AIDS"},{"key":"R26-14-20240902","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1473-3099(16)30315-2","article-title":"Finding the right dose of rifampicin, and the right dose of optimism","volume":"17","author":"Ruslami","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R27-14-20240902","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.cmi.2021.03.031","article-title":"Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: A systematic review and meta-analysis","volume":"27","author":"Onorato","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R28-14-20240902","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R29-14-20240902","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: A multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R30-14-20240902","doi-asserted-by":"crossref","first-page":"2000955","DOI":"10.1183\/13993003.00955-2020","article-title":"Increased bactericidal activity but dose-limiting intolerability at 50 mg\u00b7kg \u2212 1 rifampicin","volume":"58","author":"Te Brake","year":"2021","journal-title":"Eur Res J"},{"key":"R31-14-20240902","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12879-017-2330-z","article-title":"Drug-induced liver injury from antituberculous treatment: A retrospective study from a large TB centre in the UK","volume":"17","author":"Abbara","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R32-14-20240902","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1345\/aph.1G525","article-title":"Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection","volume":"40","author":"Lin","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R33-14-20240902","doi-asserted-by":"crossref","first-page":"e1001270","DOI":"10.1371\/journal.pmed.1001270","article-title":"Antiretroviral therapy for prevention of tuberculosis in adults with HIV: A systematic review and meta-analysis","volume":"9","author":"Suthar","year":"2012","journal-title":"PLoS Med"},{"key":"R34-14-20240902","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12890-019-0966-8","article-title":"Treatment outcomes of tuberculous meningitis in adults: A systematic review and meta-analysis","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Pulmon Med"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_135_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:02:04Z","timestamp":1787760124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_135_21"}},"subtitle":["Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_135_21","relation":{},"ISSN":["2212-5531"],"issn-type":[{"value":"2212-5531","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}